Retatrutide 10mg (LY3437943)

Name: Retatrutide 10mg
Brand: Volta Peptides
SKU: vp-002
Price: 64.00 USD
Availability: InStock

Research Use Only

12 sold this week8 people viewing this

$64 USD

Ordering above $1,000?Wholesale pricing →

All orders dispatched within 24hrs

Application formLyophilized powder

StorageRefrigerated

Purity98%

Weight10mg

CAS Number2381089-83-2

Research Use Only

For in vitro laboratory research by qualified professionals only. Not for human or animal administration. Not intended to treat, prevent, mitigate, or cure any disease. Batch-specific Certificates of Analysis available for all products.

Retatrutide is a novel triple-hormone receptor agonist peptide for metabolic research applications. This 10mg vial is ideal for initial research protocols and dose-response studies. Each batch is HPLC-verified for purity and identity.

Related Research News

Regulatory

Retatrutide Monthly Research Cost in Australia Breakdown

Researching Retatrutide (LY3437943), the most advanced triple GLP-1/GIP/glucagon receptor agonist, involves costs that vary by vial size, dose, and frequency. In Australia, a 10mg vial costs $129.99 AUD ($13.00/mg), while a 20mg vial is $199.99 AUD ($10.00/mg). Supplies like bacteriostatic water and needles add to monthly expenses, with planning around a 4-week reconstituted stability window essential to minimize waste.

May 12, 2026

Clinical Trials

Retatrutide Clinical Trial Results: Phase III TRIUMPH Data Shows Significant Weight Loss

Early reports from the Phase III TRIUMPH-1 trial suggest retatrutide, a novel triple agonist, has delivered substantial weight loss outcomes. These retatrutide clinical trial results indicate a potential shift in obesity treatment research, though full data analysis is pending.

Jun 19, 2026

Clinical Trials

Retatrutide Phase III TRIUMPH-1 Results: Unprecedented Weight Loss Reported at ADA26

Early reports from the American Diabetes Association 2026 meeting suggest retatrutide delivered unprecedented weight loss in the Phase III TRIUMPH-1 trial. Researchers and industry professionals are closely watching these retatrutide clinical trial results for implications in obesity and metabolic disease treatment.

Jun 19, 2026